{"id":"https://openalex.org/W4361240247","doi":"https://doi.org/10.1158/0008-5472.22370132","title":"Supplementary Figures 1-5 from A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity","display_name":"Supplementary Figures 1-5 from A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity","publication_year":2023,"publication_date":"2023-03-30","ids":{"openalex":"https://openalex.org/W4361240247","doi":"https://doi.org/10.1158/0008-5472.22370132"},"language":"en","primary_location":{"id":"doi:10.1158/0008-5472.22370132","doi":"https://doi.org/10.1158/0008-5472.22370132","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22370132","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/0008-5472.22370132","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5046281810","display_name":"Joseph R. Garlich","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joseph R. Garlich","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111740527","display_name":"Pradip K.R De","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Pradip De","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012509754","display_name":"Nandini Dey","orcid":"https://orcid.org/0000-0002-5533-8784","observed_orcids":["https://orcid.org/0000-0002-5533-8784"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Nandini Dey","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5086855070","display_name":"Jing Dong Su","orcid":"https://orcid.org/0000-0001-5389-734X","observed_orcids":["https://orcid.org/0000-0001-5389-734X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jing Dong Su","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5058134724","display_name":"Xiaodong Peng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Xiaodong Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5033149936","display_name":"Antoinette Miller","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antoinette Miller","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5102095257","display_name":"Ravoori Murali","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ravoori Murali","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020581776","display_name":"Yiling Lu","orcid":"https://orcid.org/0000-0002-3662-2106","observed_orcids":["https://orcid.org/0000-0002-3662-2106"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yiling Lu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005221518","display_name":"Gordon Brent Mills","orcid":"https://orcid.org/0000-0002-0144-9614","observed_orcids":["https://orcid.org/0000-0002-0144-9614"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Gordon B. Mills","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5067033760","display_name":"Vikas Kundra","orcid":"https://orcid.org/0000-0002-3262-4059","observed_orcids":["https://orcid.org/0000-0002-3262-4059"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Vikas Kundra","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072559407","display_name":"H-K. Shu","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"H-K. Shu","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025517379","display_name":"Qiong Peng","orcid":"https://orcid.org/0000-0002-8515-1136","observed_orcids":["https://orcid.org/0000-0002-8515-1136","https://orcid.org/0009-0001-3666-1359"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Qiong Peng","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5025976004","display_name":"Donald L. Durden","orcid":"https://orcid.org/0000-0001-5386-1427","observed_orcids":["https://orcid.org/0000-0001-5386-1427"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Donald L. Durden","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10952","display_name":"PI3K/AKT/mTOR signaling in cancer","score":0.9804999828338623,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.015799999237060547,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/prodrugs","display_name":"prodrugs","score":0.6470000147819519},{"id":"https://openalex.org/keywords/pi3k-inhibitors","display_name":"PI3K inhibitors","score":0.9580000042915344},{"id":"https://openalex.org/keywords/vascular-targeting","display_name":"vascular targeting","score":0.6809999942779541},{"id":"https://openalex.org/keywords/antiangiogenic-activity","display_name":"antiangiogenic activity","score":0.9110000133514404},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8899999856948853},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.4620000123977661}],"concepts":[{"id":"https://openalex.org/C108215921","wikidata":"https://www.wikidata.org/wiki/Q603741","display_name":"Prodrug","level":2,"score":0.9382892847061157},{"id":"https://openalex.org/C2781322055","wikidata":"https://www.wikidata.org/wiki/Q423725","display_name":"Phosphoinositide 3-kinase","level":4,"score":0.5573698282241821},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.540565550327301},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.4635694622993469},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.4310833811759949},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.26787325739860535},{"id":"https://openalex.org/C86554907","wikidata":"https://www.wikidata.org/wiki/Q285613","display_name":"PI3K/AKT/mTOR pathway","level":3,"score":0.2670154571533203},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.18876796960830688},{"id":"https://openalex.org/C62478195","wikidata":"https://www.wikidata.org/wiki/Q828130","display_name":"Signal transduction","level":2,"score":0.15385755896568298}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/0008-5472.22370132","doi":"https://doi.org/10.1158/0008-5472.22370132","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22370132","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/0008-5472.22370132.v1","doi":"https://doi.org/10.1158/0008-5472.22370132.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/0008-5472.22370132.v1","pdf_url":"https://aacr.figshare.com/ndownloader/files/39815210","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22370132","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Figures_1-5_from_A_Vascular_Targeted_Pan_Phosphoinositide_3-Kinase_Inhibitor_Prodrug_SF1126_with_Antitumor_and_Antiangiogenic_Activity/22370132","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/0008-5472.22370132","doi":"https://doi.org/10.1158/0008-5472.22370132","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/0008-5472.22370132","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361240247.pdf","grobid_xml":"https://content.openalex.org/works/W4361240247.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2005448885","https://openalex.org/W4361264313","https://openalex.org/W2506878738","https://openalex.org/W2241003473","https://openalex.org/W4241124341","https://openalex.org/W2023041438","https://openalex.org/W7048112156","https://openalex.org/W2123334268","https://openalex.org/W4361255276","https://openalex.org/W2042441371"],"abstract_inverted_index":{"Supplementary":[0],"Figures":[1],"1-5":[2],"from":[3],"A":[4],"Vascular":[5],"Targeted":[6],"Pan":[7],"Phosphoinositide":[8],"3-Kinase":[9],"Inhibitor":[10],"Prodrug,":[11],"SF1126,":[12],"with":[13],"Antitumor":[14],"and":[15],"Antiangiogenic":[16],"Activity":[17]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-03-31T00:00:00"}